Compare HYNE & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HYNE | PLYX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 114.1M |
| IPO Year | N/A | N/A |
| Metric | HYNE | PLYX |
|---|---|---|
| Price | $14.60 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 24.5K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $2.20 |
| 52 Week High | $14.85 | $8.15 |
| Indicator | HYNE | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 29.93 |
| Support Level | $14.01 | $2.39 |
| Resistance Level | $14.85 | $3.20 |
| Average True Range (ATR) | 0.25 | 0.50 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 53.70 | 14.29 |
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.